1. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–503.
2. US FDA. ErleadaTM (apalutamide): prescribing information. 2018.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210951s000lbl.pdf
. Accessed 26 Mar 2018.
3. Cancian M, Renzulli JF 2nd. Nonmetastatic castration-resistant prostate cancer: a modern perspective. Urology. 2018.
https://doi.org/10.1016/j.urology.2018.01.010
.
4. Rozet F, Roumeguere T, Spahn M, et al. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management. World J Urol. 2016;34(11):1505–13.
5. Janssen Pharmaceutical Companies of Johnsonson & Johnson. ERLEADA (apalutamide), a next-generation androgen receptor inhibitor, granted U.S. FDA approval for the treatment of patients with non-metastatic castration-resistant prostate cancer [media release]. 2018.
https://www.prnewswire.com/news-releases/erleada-apalutamide-a-next-generation-androgen-receptor-inhibitor-granted-us-fda-approval-for-the-treatment-of-patients-with-non-metastatic-castration-resistant-prostate-cancer-300598990.html
. Accessed 26 Mar 2018.